MoonLake Immunotherapeutics’s EPS Growth at a glance
MoonLake Immunotherapeutics reports eps growth of -158.9% for Dec 2024. The prior period recorded 66.8% (Dec 2023). Year over year the metric moved −225.7 pts (−337.8%). The rolling three-period average stands at -8.1%. Data last refreshed Dec 7, 2025, 1:30 AM.
Latest reading
-158.9% · Dec 2024
YoY movement
−225.7 pts (−337.8%)
Rolling average
-8.1%
Current EPS Growth
-158.9%
−225.7 pts
−337.8%
Rolling average
-8.1%
Latest Value
-158.9%
Dec 2024
YoY Change
−225.7 pts
Absolute
YoY Change %
−337.8%
Rate of change
3-Period Avg
-8.1%
Smoothed
Narrative signal
MoonLake Immunotherapeutics’s eps growth stands at -158.9% for Dec 2024. Year-over-year, the metric shifted by −225.7 pts, translating into a −337.8% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How eps growth shapes MoonLake Immunotherapeutics's story
As of Dec 2024, MoonLake Immunotherapeutics reports eps growth of -158.9%. Review EPS trajectory, compounding pace, and earnings momentum supported by trailing annual filings.
Understanding EPS momentum
Sustained positive EPS growth underpins long-term shareholder returns. Volatility often reflects cyclical businesses or share-count changes.
Check the drivers behind EPS
Analyze revenue growth, margin expansion, and buybacks to see which levers are powering EPS gains.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
MoonLake Immunotherapeutics (MLTX) FAQs
Answers tailored to MoonLake Immunotherapeutics’s eps growth profile using the latest Financial Modeling Prep data.
What is MoonLake Immunotherapeutics's current eps growth?
As of Dec 2024, MoonLake Immunotherapeutics reports eps growth of -158.9%. This reading reflects the latest filings and price data for MLTX.
How is MoonLake Immunotherapeutics's eps growth trending year over year?
Year-over-year, the figure shifts by −225.7 pts (−337.8%). Pair this context with revenue growth and free cash flow signals to gauge momentum for MLTX.
Why does eps growth matter for MoonLake Immunotherapeutics?
Earnings-per-share growth reveals how quickly per-share net income is expanding or contracting versus the prior year. For MoonLake Immunotherapeutics, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is MoonLake Immunotherapeutics's eps growth above its recent average?
MoonLake Immunotherapeutics's rolling three-period average sits at -8.1%. Comparing the latest reading of -158.9% to that baseline highlights whether momentum is building or fading for MLTX.
How frequently is MoonLake Immunotherapeutics's eps growth refreshed?
Data for MLTX was last refreshed on Dec 7, 2025, 1:30 AM and updates automatically every 24 hours, keeping your valuation inputs current.